Shares of Theravance THRX have rallied more than 15 percent Monday morning following some bullish comments from Piper Jaffray's M Ian Somaiya this morning.
Somaiya believes traders should watch volatility ahead of the release of FDA briefing documents for the advisory meeting for Breo on March 7th. The analyst suggested using any dip in the stock price to load up on shares.
Somaiya hinted that a positive vote from the FDA panel could aid in eventually leading to a takeover offer. The Piper analyst noted GlaxoSmithKline GSK currently holds a 26.95 percent stake in Theravance. Somaiya feels Theravance could be worth $51 per share in the event of a takeover.
Piper Jaffray maintains an Overweight rating and $32 price target on shares of Theravance.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in